NCT04866264 (eNO) is a NA clinical trial of eNutrition Optimizer in Diabetes, sponsored by Heike Bischoff-Ferrari.

Who is sponsoring NCT04866264?

NCT04866264 is sponsored by Heike Bischoff-Ferrari.

What drugs are being tested in NCT04866264?

Interventions in NCT04866264: eNutrition Optimizer.

What condition does NCT04866264 study?

NCT04866264 studies Diabetes, Hypertension, Frailty, Dementia, Cardiovascular Diseases.

Is NCT04866264 still recruiting?

NCT04866264 is currently completed. Last updated 7 August 2024.

Last reviewed 2024-08-07 · How we verify

NCT04866264: eNO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Electronic-Nutrition-Optimizer for Personalized Prevention

Completed NA Last updated 7 August 2024

What this trial tests

NA trial testing eNutrition Optimizer in Diabetes in 88 participants. Completed in 23 May 2024.

Timeline

11 November 2021

Primary endpoint
23 May 2024

23 May 2024

Quick facts

Lead sponsor	Heike Bischoff-Ferrari
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	crossover
Masking	none
Primary purpose	other
Enrollment	88
Start date	11 November 2021
Primary completion	23 May 2024
Estimated completion	23 May 2024
Sites	1 location across Switzerland

Drugs / interventions tested

eNutrition Optimizer

Conditions studied

Diabetes — all drugs for Diabetes →
Hypertension — all drugs for Hypertension →
Frailty — all drugs for Frailty →
Dementia — all drugs for Dementia →

Sponsor

Heike Bischoff-Ferrari

Who can join

50 and older, any sex, with Diabetes or Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to develop and validate a tool for immediate nutrition assessment and to test its user feasibility in routine clinical practice for health promotion.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Diabetes

Currently open trials in the same condition.

NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07479134 — Production of Stem Cells for the Generation of Pancreatic Cells · NA · recruiting
NCT07441655 — Families Implementing Good Health Traditions for Life · NA · recruiting
NCT06724172 — CHIME: Comparing Health Interventions for Maternal Equity · NA · recruiting
NCT07417865 — ECHO Diabetes FQHC · recruiting

Other Heike Bischoff-Ferrari trials

Trials by the same sponsor.

NCT05062018 — Vitamin D3 - Omega3 - Home Exercise - HeALTHy Aging and Longevity Cohort · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04866264 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Heike Bischoff-Ferrari
Last refreshed: 7 August 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04866264.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing